

## Press Release

### SYGNIS AG attends Festival of Genomics in London, UK

- One of the most important networking conferences in the field of Genomics for academia, healthcare and industry
- Confront the real issues in genomics now and in the future
- Industry leading pharmaceutical companies to discuss perspectives in precision medicine
- Festival of Genomics takes place in London, UK, January 19 to 21, 2016

Madrid, Spain and Heidelberg, Germany, January 14, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it will participate in the Festival of Genomics in London, UK, from January 19 to 21, 2016.

Miguel A. Viribay, Vice President Sales and Marketing, and Ángel Picher, Associate Director Product Development, will provide interested people from the health care sector with detailed information on the SYGNIS portfolio with focus on the recently launched SunScript™ and TruePrime™ products. The Company will have booth 3 at the congress.

The congress is an assembly of leaders in the sector who will discuss the future of medicine in the European genetics community. The Executive Chair of Genomics England, Sir John Chisholm, the Minister for Life Science, George Freeman MP and Chief Medical Officer at the Department of Health, Dame Sally Davies, will share their thoughts on the knowledge, skills and experience in using genomic medicine. In addition, executives from industry leading pharmaceutical companies including Boehringer Ingelheim, Amgen, AstraZeneca and GSK will discuss about precision medicine.

“This festival is a great opportunity for us to make our portfolio of products more visible in our most important target groups. As SYGNIS is still a smaller player we need these kind of specialized conferences to raise awareness of our Company and our kits. We are very much looking forward to discuss superiority of our products to further establish ourselves as a leading provider of innovative tools for processing genetic information for a multitude of applications,” **Miguel A. Viribay, Vice President Sales and Marketing of SYGNIS** commented.

“We will be able to meet many key decision-makers from the health care sector and show them how our kits work. The participants are experts in the field of genetic research where single cell analysis, next generation sequencing and amplification of genomic information are routine applications. Here our products can really support researchers in their daily business,” **Ángel Picher, Associate Director Product Development of SYGNIS** added.

The Festival of Genomics takes place at ExCeL London which is located at Royal Victoria Dock, 1 Western Gateway, London E16 1XL. The festival begins on the January 19, with a day packed full of focused workshops. For further information please visit <http://www.festivalofgenomicslondon.com>.

**For further information please contact:**

**SYGNIS AG**

Pilar de la Huerta  
CEO/CFO  
Phone: +34 91 192 36 50  
Email: [pdelahuerta@sygnis.com](mailto:pdelahuerta@sygnis.com)

**MC Services AG**

Raimund Gabriel  
Managing Partner  
Phone: +49 89 210228 30  
Email: [raimund.gabriel@mc-services.eu](mailto:raimund.gabriel@mc-services.eu)

**About SYGNIS AG: [www.sygnis.com](http://www.sygnis.com)**

SYGNIS, headquartered in Germany and Spain, specializes on the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to an industry leading partner, for whole genome DNA amplification and sequencing as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed at the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###